Narcolepsy Therapeutics Market by Product Type (Central Nervous System Stimulants, Sodium Oxybate, Selective Serotonin, Reuptake inhibitor (SSRI), Tricyclic Antidepressants and Others ); By Application (Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy); by Regional outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, Rest of World) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2018 - 2026

Report ID :AMI-127 | Category : Drugs By Therapeutic Area | Published Date :August, 2018 | Pages : 245 | Format :PDF
Buy Now!

Industry Trends

Narcolepsy is a neurological disorder characterized as an excessive sleepiness, sleep paralysis, hallucination and sudden loss muscle control. The chronic disorder is not a rare disease and it affects 1 among 2000 people. However, the narcolepsy is misdiagnosed or undiagnosed, hence, the actual prevalence may result to be higher than the clinician’s rate. The disorder, primarily initiates during the second decade of life stage. Yet, the affect can also be visible in young children and after the age of 40 years among people. As a result of the disorder, several therapeutics measures are being undertaken in diagnosing disabling of muscular systems and difficulties in mental health.

The Narcolepsy Therapeutics market, in terms of revenue, which was estimated at USD 4023.3 million in 2017, is expected to reach USD 6047.3 million in 2022.

Global Narcolepsy Therapeutics Market, By Region, 2018 - 2026 (USD Million)

Global Narcolepsy Therapeutics Market

Narcolepsy is a life long chronic sleep disorder that potentially affects an approximate of 0.5% of the population across the globe. The predominant symptoms of the disorder include cataplexy, excessive daytime sleepiness (EDS), sleep paralysis and hallucinations. The hallucinations generally occur during the sleep and wakefulness and are often regarded as unreal and frightening. There are large number of monitoring and surveillance tools, but very few presents in examining sleep loss and disorders issues. Hence, several initiatives such as public health campaigns are being undertaken to increase the awareness in diagnosing sleep disorders. Furthermore, specific educational strategies are also being organized among healthcare professional. Moreover, simultaneous investments in public education by individuals and organizations at national, state, local and community level clinics, hospitals and digital media. In addition, sustained efforts are also considered in integrating sleep related curriculum on undergraduate health science programs for health professionals. However, present treatment for narcolepsy are symptomatic and promote therapeutics which increase anticataleptic agents and presynaptic dopamine release. Moreover, the development of therapeutics for narcolepsy has also been challenged by the historical misunderstandings of the disease. Despite such challenges, treatments such as amphetamine, stimulants are evolving for treatment of EDS. Furthermore, gamma-hydroxybutyrate has been recently approved in treating cataplexy and EDS.

Narcolepsy Therapeutics Market, By Product Type

On the basis of the product type, sodium oxybate is expected to be the dominant segment of the global narcolepsy therapeutics market. Sodium oxybate drug is recognized as a complete solution for all the symptoms of narcolepsy diseases. In addition, the drug goes not have any adverse side effects and are the most recommended drug by the doctors. Hence, the growth of narcolepsy disease increases the demand for sodium oxybate.

Narcolepsy Therapeutics  Market, By Region

North America region is expected to hold largest market share in the global narcolepsy therapeutics market. The narcolepsy disease is most prone in the North America region. Furthermore, it is estimated that around 1 among 2000 people are affected by the condition. The favorable reimbursement policies associated with drugs are surging the market to grow in the region. Moreover, many organization are actively involving in spreading awareness and education related sleep paralysis, EDS and cataplexy disorder. In addition, the ongoing establishments, R&D of novel drugs are some of the other factors that are fueling the market to grow in the region.

Competitive Landscape

The narcolepsy therapeutics market report provides both, subjective and quantitative research of the market, as well as integrates worthy insights into the rational scenario and favored development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as M&A, affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their manufacturing base, competitors, product type, application and specification, pricing, and gross margin.

Some of the primary market participants are Addrenex Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals PLC, Arena Pharmaceuticals, Inc., BIOPROJET, Shire, Ligand Pharmaceuticals, Inc., amongst others.

 Narcolepsy Therapeutics Industry Background

Global Narcolepsy Therapeutics Market

Global Narcolepsy Therapeutics Market

1.    Introduction

1.1.   Market Scope

1.2.   Market Segmentation

1.3.   Methodology

1.4.   Assumptions

2.    Narcolepsy Therapeutics Market Snapshot

3.    Executive Summary: Narcolepsy Therapeutics Market

4.    Qualitative Analysis: Narcolepsy Therapeutics Market

4.1.   Introduction

4.1.1.   Product Definition

4.1.2.   Industry Development

4.2.   Market Dynamics

4.2.1.   Drivers

4.2.2.   Restraints

4.2.3.   Opportunities

4.3.   Trends in Market

5.    Global Narcolepsy Therapeutics Market Analysis and Forecasts, 2018 – 2026

5.1.   Overview

5.1.1.   Global Market Revenue (US$ Mn) and Forecasts

5.2.   Global Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

5.2.1.   Central nervous system stimulants

5.2.1.1.    Definition

5.2.1.2.    Market Penetration

5.2.1.3.    Market Revenue Expected to Increase by 2026

5.2.1.4.    Compound Annual Growth Rate (CAGR)

5.2.2.   Sodium Oxybate

5.2.2.1.    Definition

5.2.2.2.    Market Penetration

5.2.2.3.    Market Revenue Expected to Increase by 2026

5.2.2.4.    Compound Annual Growth Rate (CAGR)

5.2.3.   Selective Serotonin Reuptake Inhibitor (SSRI)

5.2.3.1.    Definition

5.2.3.2.    Market Penetration

5.2.3.3.    Market Revenue Expected to Increase by 2026

5.2.3.4.    Compound Annual Growth Rate (CAGR)

5.2.4.   Tricyclic Antidepressants

5.2.4.1.    Definition

5.2.4.2.    Market Penetration

5.2.4.3.    Market Revenue Expected to Increase by 2026

5.2.4.4.    Compound Annual Growth Rate (CAGR)

5.2.5.   Others

5.2.5.1.    Definition

5.2.5.2.    Market Penetration

5.2.5.3.    Market Revenue Expected to Increase by 2026

5.2.5.4.    Compound Annual Growth Rate (CAGR)

5.3.   Key Segment for Channeling Investments

5.3.1.   By Product Type

6.    Global Narcolepsy Therapeutics Market Analysis and Forecasts, 2018 – 2026

6.1.   Overview

6.2.   Global Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

6.2.1.   Narcolepsy With Cataplexy

6.2.1.1.    Definition

6.2.1.2.    Market Penetration

6.2.1.3.    Market Revenue Expected to Increase by 2026

6.2.1.4.    Compound Annual Growth Rate (CAGR)

6.2.2.   Narcolepsy Without Cataplexy

6.2.2.1.    Definition

6.2.2.2.    Market Penetration

6.2.2.3.    Market Revenue Expected to Increase by 2026

6.2.2.4.    Compound Annual Growth Rate (CAGR)

6.2.3.   Secondary Narcolepsy

6.2.3.1.    Definition

6.2.3.2.    Market Penetration

6.2.3.3.    Market Revenue Expected to Increase by 2026

6.2.3.4.    Compound Annual Growth Rate (CAGR)

6.3.   Key Segment for Channeling Investments

6.3.1.   By Application

7.    North America Narcolepsy Therapeutics Market Analysis and Forecasts, 2018 – 2026

7.1.   Overview

7.1.1.   North America Narcolepsy Therapeutics Market Revenue (US$ Mn)

7.2.   North America Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

7.2.1.   Central nervous system stimulants

7.2.2.   Sodium Oxybate

7.2.3.   Selective Serotonin Reuptake Inhibitor (SSRI)

7.2.4.   Tricyclic Antidepressants

7.2.5.   Others

7.3.   North America Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

7.3.1.   Narcolepsy With Cataplexy

7.3.2.   Narcolepsy Without Cataplexy

7.3.3.   Secondary Narcolepsy

7.4.   North America Market Revenue (US$ Mn) and Forecasts, By Country

7.4.1.   U.S.

7.4.1.1.    U.S. Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

7.4.1.1.1.    Central nervous system stimulants

7.4.1.1.2.    Sodium Oxybate

7.4.1.1.3.    Selective Serotonin Reuptake Inhibitor (SSRI)

7.4.1.1.4.    Tricyclic Antidepressants

7.4.1.1.5.    Others

7.4.1.2.    U.S. Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

7.4.1.2.1.    Narcolepsy With Cataplexy

7.4.1.2.2.    Narcolepsy Without Cataplexy

7.4.1.2.3.    Secondary Narcolepsy

7.4.2.   Rest of North America

7.4.2.1.    Rest of North America Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

7.4.2.1.1.    Central nervous system stimulants

7.4.2.1.2.    Sodium Oxybate

7.4.2.1.3.    Selective Serotonin Reuptake Inhibitor (SSRI)

7.4.2.1.4.    Tricyclic Antidepressants

7.4.2.1.5.    Others

7.4.2.2.    Rest of North America Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

7.4.2.2.1.    Narcolepsy With Cataplexy

7.4.2.2.2.    Narcolepsy Without Cataplexy

7.4.2.2.3.    Secondary Narcolepsy

7.5.   Key Segment for Channeling Investments

7.5.1.   By Country

7.5.2.   By Product Type

7.5.3.   By Application

8.    Europe Narcolepsy Therapeutics Market Analysis and Forecasts, 2018 – 2026

8.1.   Overview

8.1.1.   Europe Market Revenue (US$ Mn)

8.2.   Europe Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

8.2.1.   Central nervous system stimulants

8.2.2.   Sodium Oxybate

8.2.3.   Selective Serotonin Reuptake Inhibitor (SSRI)

8.2.4.   Tricyclic Antidepressants

8.2.5.   Others

8.3.   Europe Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

8.3.1.   Narcolepsy With Cataplexy

8.3.2.   Narcolepsy Without Cataplexy

8.3.3.   Secondary Narcolepsy

8.4.   Europe Market Revenue (US$ Mn) and Forecasts, By Country

8.4.1.   France

8.4.1.1.    France Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

8.4.1.1.1.    Central nervous system stimulants

8.4.1.1.2.    Sodium Oxybate

8.4.1.1.3.    Selective Serotonin Reuptake Inhibitor (SSRI)

8.4.1.1.4.    Tricyclic Antidepressants

8.4.1.1.5.    Others

8.4.1.2.    France Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

8.4.1.2.1.    Narcolepsy With Cataplexy

8.4.1.2.2.    Narcolepsy Without Cataplexy

8.4.1.2.3.    Secondary Narcolepsy

8.4.2.   The UK

8.4.2.1.    The UK Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

8.4.2.1.1.    Central nervous system stimulants

8.4.2.1.2.    Sodium Oxybate

8.4.2.1.3.    Selective Serotonin Reuptake Inhibitor (SSRI)

8.4.2.1.4.    Tricyclic Antidepressants

8.4.2.1.5.    Others

8.4.2.2.    The UK Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

8.4.2.2.1.    Narcolepsy With Cataplexy

8.4.2.2.2.    Narcolepsy Without Cataplexy

8.4.2.2.3.    Secondary Narcolepsy

8.4.3.   Spain

8.4.3.1.    Spain Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

8.4.3.1.1.    Central nervous system stimulants

8.4.3.1.2.    Sodium Oxybate

8.4.3.1.3.    Selective Serotonin Reuptake Inhibitor (SSRI)

8.4.3.1.4.    Tricyclic Antidepressants

8.4.3.1.5.    Others

8.4.3.2.    Spain Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

8.4.3.2.1.    Narcolepsy With Cataplexy

8.4.3.2.2.    Narcolepsy Without Cataplexy

8.4.3.2.3.    Secondary Narcolepsy

8.4.4.   Germany

8.4.4.1.    Germany Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

8.4.4.1.1.    Central nervous system stimulants

8.4.4.1.2.    Sodium Oxybate

8.4.4.1.3.    Selective Serotonin Reuptake Inhibitor (SSRI)

8.4.4.1.4.    Tricyclic Antidepressants

8.4.4.1.5.    Others

8.4.4.2.    Germany Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

8.4.4.2.1.    Narcolepsy With Cataplexy

8.4.4.2.2.    Narcolepsy Without Cataplexy

8.4.4.2.3.    Secondary Narcolepsy

8.4.5.   Italy

8.4.5.1.    Italy Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

8.4.5.1.1.    Central nervous system stimulants

8.4.5.1.2.    Sodium Oxybate

8.4.5.1.3.    Selective Serotonin Reuptake Inhibitor (SSRI)

8.4.5.1.4.    Tricyclic Antidepressants

8.4.5.1.5.    Others

8.4.5.2.    Italy Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

8.4.5.2.1.    Narcolepsy With Cataplexy

8.4.5.2.2.    Narcolepsy Without Cataplexy

8.4.5.2.3.    Secondary Narcolepsy

8.4.6.   Rest of Europe

8.4.6.1.    Rest of Europe Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

8.4.6.1.1.    Central nervous system stimulants

8.4.6.1.2.    Sodium Oxybate

8.4.6.1.3.    Selective Serotonin Reuptake Inhibitor (SSRI)

8.4.6.1.4.    Tricyclic Antidepressants

8.4.6.1.5.    Others

8.4.6.2.    Rest of Europe Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

8.4.6.2.1.    Narcolepsy With Cataplexy

8.4.6.2.2.    Narcolepsy Without Cataplexy

8.4.6.2.3.    Secondary Narcolepsy

8.5.   Key Segment for Channeling Investments

8.5.1.   By Country

8.5.2.   By Product Type

8.5.3.   By Application

9.    Asia Pacific Narcolepsy Therapeutics Market Analysis and Forecasts, 2018 – 2026

9.1.   Overview

9.1.1.   Asia Pacific Market Revenue (US$ Mn)

9.2.   Asia Pacific Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

9.2.1.   Central nervous system stimulants

9.2.2.   Sodium Oxybate

9.2.3.   Selective Serotonin Reuptake Inhibitor (SSRI)

9.2.4.   Tricyclic Antidepressants

9.2.5.   Others

9.3.   Asia Pacific Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

9.3.1.   Narcolepsy With Cataplexy

9.3.2.   Narcolepsy Without Cataplexy

9.3.3.   Secondary Narcolepsy

9.4.   Asia Pacific Market Revenue (US$ Mn) and Forecasts, By Country

9.4.1.   China

9.4.1.1.    China Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

9.4.1.1.1.    Central nervous system stimulants

9.4.1.1.2.    Sodium Oxybate

9.4.1.1.3.    Selective Serotonin Reuptake Inhibitor (SSRI)

9.4.1.1.4.    Tricyclic Antidepressants

9.4.1.1.5.    Others

9.4.1.2.    China Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

9.4.1.2.1.    Narcolepsy With Cataplexy

9.4.1.2.2.    Narcolepsy Without Cataplexy

9.4.1.2.3.    Secondary Narcolepsy

9.4.2.   Japan

9.4.2.1.    Japan Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

9.4.2.1.1.    Central nervous system stimulants

9.4.2.1.2.    Sodium Oxybate

9.4.2.1.3.    Selective Serotonin Reuptake Inhibitor (SSRI)

9.4.2.1.4.    Tricyclic Antidepressants

9.4.2.1.5.    Others

9.4.2.2.    Japan Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

9.4.2.2.1.    Narcolepsy With Cataplexy

9.4.2.2.2.    Narcolepsy Without Cataplexy

9.4.2.2.3.    Secondary Narcolepsy

9.4.3.   India

9.4.3.1.    India Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

9.4.3.1.1.    Central nervous system stimulants

9.4.3.1.2.    Sodium Oxybate

9.4.3.1.3.    Selective Serotonin Reuptake Inhibitor (SSRI)

9.4.3.1.4.    Tricyclic Antidepressants

9.4.3.1.5.    Others

9.4.3.2.    India Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

9.4.3.2.1.    Narcolepsy With Cataplexy

9.4.3.2.2.    Narcolepsy Without Cataplexy

9.4.3.2.3.    Secondary Narcolepsy

9.4.4.   Southeast Asia

9.4.4.1.    Southeast Asia Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

9.4.4.1.1.    Central nervous system stimulants

9.4.4.1.2.    Sodium Oxybate

9.4.4.1.3.    Selective Serotonin Reuptake Inhibitor (SSRI)

9.4.4.1.4.    Tricyclic Antidepressants

9.4.4.1.5.    Others

9.4.4.2.    Southeast Asia Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

9.4.4.2.1.    Narcolepsy With Cataplexy

9.4.4.2.2.    Narcolepsy Without Cataplexy

9.4.4.2.3.    Secondary Narcolepsy

9.4.5.   Rest of Asia Pacific

9.4.5.1.    Rest of Asia Pacific Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

9.4.5.1.1.    Central nervous system stimulants

9.4.5.1.2.    Sodium Oxybate

9.4.5.1.3.    Selective Serotonin Reuptake Inhibitor (SSRI)

9.4.5.1.4.    Tricyclic Antidepressants

9.4.5.1.5.    Others

9.4.5.2.    Rest of Asia Pacific Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

9.4.5.2.1.    Narcolepsy With Cataplexy

9.4.5.2.2.    Narcolepsy Without Cataplexy

9.4.5.2.3.    Secondary Narcolepsy

9.5.   Key Segment for Channeling Investments

9.5.1.   By Country

9.5.2.   By Product Type

9.5.3.   By Application

10. Middle East and Africa Narcolepsy Therapeutics Market Analysis and Forecasts, 2018 – 2026

10.1. Overview

10.1.1. Middle East and Africa Market Revenue (US$ Mn)

10.2. Middle East and Africa Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

10.2.1. Central nervous system stimulants

10.2.2. Sodium Oxybate

10.2.3. Selective Serotonin Reuptake Inhibitor (SSRI)

10.2.4. Tricyclic Antidepressants

10.2.5. Others

10.3. Middle East and Africa Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

10.3.1. Narcolepsy With Cataplexy

10.3.2. Narcolepsy Without Cataplexy

10.3.3. Secondary Narcolepsy

10.4. Middle East and Africa Market Revenue (US$ Mn) and Forecasts, By Country

10.4.1. GCC Countries

10.4.1.1.  GCC Countries Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

10.4.1.1.1.  Central nervous system stimulants

10.4.1.1.2.  Sodium Oxybate

10.4.1.1.3.  Selective Serotonin Reuptake Inhibitor (SSRI)

10.4.1.1.4.  Tricyclic Antidepressants

10.4.1.1.5.  Others

10.4.1.2.  GCC Countries Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

10.4.1.2.1.  Narcolepsy With Cataplexy

10.4.1.2.2.  Narcolepsy Without Cataplexy

10.4.1.2.3.  Secondary Narcolepsy

10.4.2. Southern Africa

10.4.2.1.  Southern Africa Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

10.4.2.1.1.  Central nervous system stimulants

10.4.2.1.2.  Sodium Oxybate

10.4.2.1.3.  Selective Serotonin Reuptake Inhibitor (SSRI)

10.4.2.1.4.  Tricyclic Antidepressants

10.4.2.1.5.  Others

10.4.2.2.  Southern Africa Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

10.4.2.2.1.  Narcolepsy With Cataplexy

10.4.2.2.2.  Narcolepsy Without Cataplexy

10.4.2.2.3.  Secondary Narcolepsy

10.4.3. Rest of MEA

10.4.3.1.  Rest of MEA Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

10.4.3.1.1.  Central nervous system stimulants

10.4.3.1.2.  Sodium Oxybate

10.4.3.1.3.  Selective Serotonin Reuptake Inhibitor (SSRI)

10.4.3.1.4.  Tricyclic Antidepressants

10.4.3.1.5.  Others

10.4.3.2.  Rest of MEA Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

10.4.3.2.1.  Narcolepsy With Cataplexy

10.4.3.2.2.  Narcolepsy Without Cataplexy

10.4.3.2.3.  Secondary Narcolepsy

10.5. Key Segment for Channeling Investments

10.5.1. By Country

10.5.2. By Product Type

10.5.3. By Application

11. Latin America Narcolepsy Therapeutics Market Analysis and Forecasts, 2018 – 2026

11.1. Overview

11.1.1. Latin America Market Revenue (US$ Mn)

11.2. Latin America Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

11.2.1. Central nervous system stimulants

11.2.2. Sodium Oxybate

11.2.3. Selective Serotonin Reuptake Inhibitor (SSRI)

11.2.4. Tricyclic Antidepressants

11.2.5. Others

11.3. Latin America Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

11.3.1. Narcolepsy With Cataplexy

11.3.2. Narcolepsy Without Cataplexy

11.3.3. Secondary Narcolepsy

11.4. Latin America Market Revenue (US$ Mn) and Forecasts, By Country

11.4.1. Brazil

11.4.1.1.  Brazil Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

11.4.1.1.1.  Central nervous system stimulants

11.4.1.1.2.  Sodium Oxybate

11.4.1.1.3.  Selective Serotonin Reuptake Inhibitor (SSRI)

11.4.1.1.4.  Tricyclic Antidepressants

11.4.1.1.5.  Others

11.4.1.2.  Brazil Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

11.4.1.2.1.  Narcolepsy With Cataplexy

11.4.1.2.2.  Narcolepsy Without Cataplexy

11.4.1.2.3.  Secondary Narcolepsy

11.4.2. Rest of Latin America

11.4.2.1.  Rest of Latin America Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Product Type

11.4.2.1.1.  Central nervous system stimulants

11.4.2.1.2.  Sodium Oxybate

11.4.2.1.3.  Selective Serotonin Reuptake Inhibitor (SSRI)

11.4.2.1.4.  Tricyclic Antidepressants

11.4.2.1.5.  Others

11.4.2.2.  Rest of Latin America Narcolepsy Therapeutics Market Revenue (US$ Mn) and Forecasts, By Application

11.4.2.2.1.  Narcolepsy With Cataplexy

11.4.2.2.2.  Narcolepsy Without Cataplexy

11.4.2.2.3.  Secondary Narcolepsy

11.5. Key Segment for Channeling Investments

11.5.1. By Country

11.5.2. By Product Type

11.5.3. By Application

12. Competitive Benchmarking

12.1. Player Positioning Analysis

12.2. Global Presence and Growth Strategies

13. Player Profiles

13.1. Addrenex Pharmaceuticals, Inc.

13.1.1. Company Details

13.1.2. Company Overview

13.1.3. Product Offerings

13.1.4. Key Developments

13.1.5. Financial Analysis

13.1.6. SWOT Analysis

13.1.7. Business Strategies

13.2. Teva Pharmaceutical Industries Ltd.

13.2.1. Company Details

13.2.2. Company Overview

13.2.3. Product Offerings

13.2.4. Key Developments

13.2.5. Financial Analysis

13.2.6. SWOT Analysis

13.2.7. Business Strategies

13.3. Jazz Pharmaceuticals PLC

13.3.1. Company Details

13.3.2. Company Overview

13.3.3. Product Offerings

13.3.4. Key Developments

13.3.5. Financial Analysis

13.3.6. SWOT Analysis

13.3.7. Business Strategies

13.4. Arena Pharmaceuticals, Inc.

13.4.1. Company Details

13.4.2. Company Overview

13.4.3. Product Offerings

13.4.4. Key Developments

13.4.5. Financial Analysis

13.4.6. SWOT Analysis

13.4.7. Business Strategies

13.5. BIOPROJET

13.5.1. Company Details

13.5.2. Company Overview

13.5.3. Product Offerings

13.5.4. Key Developments

13.5.5. Financial Analysis

13.5.6. SWOT Analysis

13.5.7. Business Strategies

13.6. Shire

13.6.1. Company Details

13.6.2. Company Overview

13.6.3. Product Offerings

13.6.4. Key Developments

13.6.5. Financial Analysis

13.6.6. SWOT Analysis

13.6.7. Business Strategies

13.7. Ligand Pharmaceuticals, Inc.

13.7.1. Company Details

13.7.2. Company Overview

13.7.3. Product Offerings

13.7.4. Key Developments

13.7.5. Financial Analysis

13.7.6. SWOT Analysis

13.7.7. Business Strategies

 

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

At Absolute Markets Insights, we use both top-down and bottom-up approach for calculating the market estimates and market forecast data. We allocate year-on-year growth rate from 2018 to 2026 and reach to the calculations for the global CAGR. Basically for estimation of the products and applications, usually we follow bottom-up approach, where we track the trends in different regions and their countries. We track down the growth factors, restraints, rules & regulations and opportunities for each country and its region and finally calculate the global numbers. We first track the growth for the U.S. and Rest of North America. With these factors we can estimate the growth and trend for North America, similar approach would be taken for Europe, Asia Pacific, Latin America and Middle East & Africa. Finally, through our home grown model we reach to estimation and forecasting of the global numbers.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

Research Methodology

Methodology

Key Inclusions

Methodology

  • A PHP Error was encountered

    Severity: Notice

    Message: Undefined offset: 0

    Filename: pages/reportpage.php

    Line Number: 204

    Backtrace:

    File: /home/absolute/public_html/application/views/pages/reportpage.php
    Line: 204
    Function: _error_handler

    File: /home/absolute/public_html/application/controllers/Report.php
    Line: 153
    Function: view

    File: /home/absolute/public_html/index.php
    Line: 315
    Function: require_once